<DOC>
	<DOC>NCT01788371</DOC>
	<brief_summary>To explore the antiviral effect of nucleoside analogue in late pregnancy and the safety of the antiviral drug to fetus.To establish the best therapy strategy to pregnant women with high level of HBV DNA.</brief_summary>
	<brief_title>Nucleoside Analogue Prevent Vertical Transmission of Hepatitis B Virus</brief_title>
	<detailed_description>Telbivudine and Lamivudine,a preganancy category B medication,reduces HBV DNA and normalizes serum ALT in chronic hepatitis B patients with few adverse effects.Two aspects on the drug use in pregnancy will be evaluated prospectively in this study.</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Viremia</mesh_term>
	<mesh_term>Telbivudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>HBeAg+CHB pregnant woman gestational age 28 weeks HBVDNA&gt;log10 copies/ml coinfection with hepatitis A,C,D,E or HIV evidence of hepatocellular carcinoma decompensated liver disease or significant comorbidity concurrent treatment with immunemodulators,cytotoxic drugs,or steroids clinical signs of threatened miscarriage in early prenancy evidence of fetal deformity by ultrasound examination the biological father of the child had CHB</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>